The carcinogenic potential of prednisone, a synthetic corticosteroid used as an anti-inflammatory and immunosuppressive agent, was investigated by feeding it to Cr1:CD-1(ICR) mice (50/sex/dose) at doses of 0.25, 0.50, 1.0, and 5.0 mg/kg/day for 18 months. Prednisone did not significantly increase the incidence of neoplasms ( p &le; 0.05); on the contrary, it significantly decreased the incidence of hepatocellular tumors (p = 0.002 in males, p = 0.027 in females), male lacrimal/Harderian gland tumors ( p = 0.05), female pulmonary adenomas (p = 0.047), female endothelial cell tumors (p = 0.035), and female lymphosarcomas ( p = 0.02).
INTRODUCTION
Prednisone is a synthetic corticosteroid with potent anti-inflammatory, immunosuppressive, and lymphocytolytic properties. Because it is used to treat a wide range of disorders, human doses vary widely. The usual maintenance dose is 10-20 mg/ day (0.1-0.3 mg/kg/day), but doses 10 times larger are sometimes given to treat lymphoid neoplasms or suppress organ transplant rejection (12) .
Prednisone is rapidly converted to its active metabolite, prednisolone, in people and animals (15) . After oral administration of prednisone to dogs, serum concentrations ofprednisone and prednisolone peak at 1 hr (5); in mice, concentrations peak at 15 min (9) . In 1981, IARC (the International Agency for Research on Cancer) concluded that available data from in vitro mutagenicity tests, animal experiments, and epidemiology studies were inadequate to evaluate prednisone's carcinogenicity in humans (21 ) . Their report discussed only 2 animal experiments. In one (29) , Weisburger gave rats and mice (25/sex/dose) intraperitoneal prednisone injections (6 or 12 mg/ kg in mice, 1 i or 22 mg/kg in rats) thrice weekly for 6 months, observed them another 12 months, and killed them. She reported that prednisone doubled the incidence of neoplasms in female rats but did not alter the incidence in mice or male rats; however, IARC considered that inadequate reporting of certain items, amalgamation of various experimental groups and tumor types, and lack of age-adjustment in the analyses precluded evaluation of the study. In the other experiment (16), Koranda and others fed 40 female mice a diet containing 30 mg prednisone/kg of food for 4 months, then 1 containing 20 mg prednisone/kg of food for another 3 months, and then killed them. They irradiated half the mice with ultraviolet radiation 5 days a week; squamous cell carcinomas occurred in 3/17 irradiated mice, but no neoplasms occurred in the rest.
In 1986, Berger and his coworkers (3) reported that prednisone was not carcinogenic in female Sprague-Dawley rats given 3 mg/kg by gavage l, 2, 4.5, or 9 times a month for 18 months. Our study investigated prednisone's carcinogenicity in CD-1 I mice fed up to 5 mg/kg/day for 18 months.
METHODS

Test Material
Prednisone, 17,21-dihydroxy-pregna-1,4-diene-3,11,20-trione, was given by mixing it in rodent chow (Certified Rodent Chow #5002, Purina Mills Inc., St. Louis, MO). Its purity and 3-week stability in rodent chow were measured prior to initiating this study. Test diet samples approximating the anticipated range of dietary prednisone concentrations were analyzed for uniformity of prednisone content prior to initiating this study to ensure that mixing procedures were adequate. Test diets were analyzed for prednisone concentration during week 1 and at 3-month intervals thereafter.
Experimental Animals and Design
Male and female Crl: CD-1 (ICR) mice, approximately 4-weeks-old, were obtained from Charles River Laboratories, Portage, MI. During a 2-week acclimation period, they were identified by tail tattoos and cage cards and randomly assigned to a control and 4 treatment groups of 50 mice/sex. Dietary doses of 0, 0.25, 0.5, 1.0, and 5.0 mg prednisone/kg/day were given for 18 months. Doses were based upon body weight decreases seen in a previous 13- week dose-range-finding study.
Mice were cared for and used as recommended in the Guide for the Care and Use of Laboratory Animals (6) . They were housed individually in suspended, wire-bottomed, stainless steel cages in a single room with controlled temperature, humidity, and light/dark cycles. Periodically, cage racks were rotated clockwise in the room and rows of cages in each rack were rotated top to bottom. Deionized well water, analyzed periodically for compliance with EPA potable water standards, and test diets were provided ad libitum. Dietary prednisone concentrations were adjusted weekly for the first 3 months, every 2 weeks for the next Mice were observed daily for changes in behavior or physical appearance. Body weights and food consumption were measured weekly for the first 3 months, every 2 weeks for the next 3 months, and monthly, thereafter. Mice were palpated monthly and the location, dimensions, appearance, and progression of masses were recorded.
Hematology
To screen mice for leukemias, cardiac blood samples were collected from mice killed moribund and at the scheduled necropsy. Samples were analyzed for packed cell volume, hemoglobin, and total red and white cell counts. If mice had white blood cell counts 2:: 10,000/mm3, blood smears were prepared and examined.
Pathology
Moribund mice were killed by CO, inhalation to minimize suffering and postmortem autolysis. At the scheduled necropsy, mice were anesthetized by methoxyfluorane inhalation and killed by exsanguination. All mice were necropsied and examined for gross lesions. At the scheduled necropsy, brain, heart, liver, kidneys, gonads, and spleen were weighed. All tissues/organs, including the carcass, were fixed in 10% buffered formalin.
Representative samples of selected fixed tissues were stained with hematoxylin and eosin and examined microscopically:
In addition, grossly visible masses, nodules, or other lesions suspected of being tumors were processed in the same way and examined microscopically. Based on all observations, an attempt was made to determine a cause of death or morbidity for each mouse that died spontaneously or was killed moribund. All tumors were classified as incidental or fatal.
Statistical Analysis '
Data were analyzed for dose-related trends. Body weight and food consumption were summarized in each of 2 time intervals for each mouse, then analyzed for 1-tailed negative trends in dose by linear regression (23) . Each dose group's survival probability was estimated by Kaplan and Meier's method, then differences were analyzed by non-parametic log-rank tests (19) . Hematology data were analyzed using step-down linear regression (28).
&dquo;
Tumor data were analyzed using a survival-adjusted test for trends in proportions (2) that is well-behaved under various degrees of tumor and treatment lethality. Because most tumors were incidental, incidental and fatal tumors were combined TABLE L-Calculated daily prednisone doses.a a Dose (mg/kg/day) = C(FC/BW), where FC is the group mean food consumption (g/day) for the study interval, BW is the group mean body weight (g) at the end of the study interval, and C is the actual analyzed test material concentration in the diet (mg/kg) for the study interval. for analysis. For completeness, incidental and fatal tumors also were analyzed separately, and combined tumor data were analyzed using the life table test (10) , which treats all tumors as fatal. All tests were 1-tailed for a dose-related increase in tumor incidence on a log-dose scale. Certain morphologic types of tumors in the same organ or tissue and certain tumor sites were combined for trend analysis as suggested by McConnell et al (18) . These combinations are evident from the tumor tables. Data were considered insufficient for trend analysis if a tumor type occurred in only one mouse across all dose groups.
For tumor data, the inflated false positive error rate associated with multiple tests in the same set of mice (26) was controlled in a separate analysis by Westfall and Young's method (31 ) . Analysis of other data was not so controlled. The final toxicologic interpretation of data considered factors such as dose-response relationships, biological plausibility, and consistency.
RESULTS
Test Material
Dietary prednisone concentrations measured at intervals during the study were 81-117% of theoretical. Actual daily doses (calculated from these concentrations, food consumption, and body weights) varied less; they were 86-104% of theoretical (Table I) .
In-Life Observations
Treatment-related clinical observations were those expected with hypercorticism: alopecia and an increased incidence of bacterial infections (Table II) . Compared to controls, more mice given = 1.0 mg/ kg/day had thin haircoats or alopecia. More highdose mice had abscesses or cloudy eyes due to keratitis or anterior uveitis; more high-dose males had swollen preputial glands. Histopathologically, keratitis and uveitis were suppurative processes consistent with infection, and bacterial colonies were observed in most abscesses and swollen preputial glands.
Fewer high-dose mice than controls survived treatment: 18-month survival rates of mice given <_ 1.0 mg/kg/day were 80-94% for males and 74-82% for females, but survival rates of high-dose mice were only 44% for males and 52% for females ( Fig. 1 ). Infections were the main causes of death in high-dose mice (Table III) ; together with hemothorax, they accounted for this group's significantly decreased (p s 0.05) survival. Although the incidence of amyloidosis was unaffected by prednisone, fewer high-dose females than controls died of amy- loidosis, partly offsetting the increase in deaths from infection and hemothorax. Prednisone did not affect the incidence of fatal neoplasms. Prednisone suppressed growth more severely and at a lower dose in males than females (Fig. 2) . Growth suppression was accompanied by reduced food consumption early in the study, but body weights remained significantly lower even after food consumption effects disappeared. The MTD (maximum tolerated dose), defined as the highest prednisone dose that decreased weight less than 10% throughout treatment and did not decrease survival, was 0.5 mg/kg/day in males and 1.0 mg/kg/day in females.
Hematology
No treatment-related effects were detected in mice killed at the scheduled necropsy. Twenty-one mice killed moribund during treatment or at the scheduled necropsy had white blood cell counts ~~ 10,000/ mm3: 2 had lymphocytic leukemia associated with multi-organ lymphosarcoma; 15 had neutrophilia secondary to infection/inflammation, tumor necro-sis, or traumatic tissue damage; and the other 4 had neutrophilia associated with myeloid hyperplasia and extramedullary hematopoiesis, but no stimulus for increased neutrophil production was found.
Non-Neoplastic Pathologic Observations
Treatment-related low body weights were accompanied by low liver, spleen, ovary, and male heart weights. Decreases in liver and heart weights were proportional to body weight; decreases in spleen and ovary weights were greater, due to splenic lymphoid depletion and a decreased incidence of ovarian cysts.
Treatment-related gross and histopathologic changes (Tables IV and V) were attributed chiefly to the metabolic and immunosuppressive (27) properties of prednisone. Changes included: 1) Decreased incidence of nonspecific subacute-to-chronic inflammation, characterized by multifocal lymphocytic or mixed mononuclear cell infiltration, in lacrimal glands, liver, pancreas, salivary gland, stomach, and urinary bladder. 2) Increased incidence of suppurative or necrotizing inflammation in eyes, kidneys, and male accessory sex glands. Because the study focused on tumor formation, no attempt was made to culture these lesions to identify infectious agents; however, bacterial colonies were often observed microscopically in kidney and sex gland lesions, and suppurative inflammation in eyes was consistent with infection. 3) Increased incidence of small spleens due to lymphoid depletion in highdose mice. 4) Increased incidence of small adrenal glands due to cortical atrophy and degeneration in males at all doses and females given ~1.0 mg/kg/ day. Degeneration _was characterized by accumulation of large cells with abundant golden-brown foamy cytoplasm at the corticomedullary junction. 5) De-creased incidence of hepatocellular microvesicular vacuoles in males given = 1.0 mg/kg/day and highdose females due to decreased glycogen accumulation. 6) Slightly increased incidence of small testicles and seminiferous tubule degeneration at all doses. 7) Increased incidence of hemothorax in high-dose mice. Hemothorax was not due to clotting defects, because bleeding at other sites was never observed.
Instead, hemothorax was most likely due to rupture of blood vessels weakened by prednisone-related changes in collagen production (20) ..
High-dose females had a decreased incidence of ovarian cysts, but since cysts are more common in older mice this may have been due solely to de- Prednisone caused statistically significant negative trends in hepatocellular tumors (p = 0.002 in males, p = 0.027 in females), male lacrimallHarderian gland tumors (p = 0.05), female bronchoalveolar adenonias (p = 0.047), female endothelial cell tumors (p = 0.035), and female lymphosarcomas (p = 0.02).. ,
DISCUSSION
Prednisone was not carcinogenic in mice under the conditions of this study. In fact, it was anticar-cinogenic in the sense that it decreased the incidence of several common mouse neoplasms. The negative trend in lymphosarcomas was expected because prednisone is lymphocytolytic (27) , corticosteroids in general cause regression of transplanted lymphosarcomas in mice (13, 14) , and prednisone in particular is used to treat lymphosarcoma in people and animals (8, 12, 17) . The negative trends in other types of tumors may have been related partly to reduced weight gain, lower mature body weights, and altered metabolism associated with prednisone (7, 22) . For example, reduced caloric intake leading to slower growth and lower body weights is associated with decreased liver tumor incidence in mice (11) .
' '
The influence of corticosteroids on chemically induced-rodent tumors has been studied by several investigators with conflicting results. (reviewed in 24). For example, weekly intraperitoneal injections of 0.5 mg prednisolone inhibit development of DMBA (dimethybenzanthracene)-induced submandibular gland fibrosarcomas in hamsters (4), but systemically administered cortisone hastens development of DMBA-induced submandibular gland carcinomas in rats (1) and buccal pouch carcinomas in hamsters (25) . In mice, oral administration of One-tailed trend p-value. Trend was analyzed only if a tumor type occurred in more than I mouse/sex. b Number in parentheses is the number of mice from which this tissue/organ was examined. 6-methylprednisolone for 3 consecutive days accelerates development of DMBA-induced forestomach papillomas (29) and twice weekly injections of fluocinolone acetonide accelerate the development of DMBA-induced dermal papillomas and carcinomas (32) . How corticosteroids inhibit or augment development of chemically induced neoplasms has not been delineated in any of these studies, so they shed no light on our results. Nevertheless, our study suggests that longterm (lifetime) prednisone treatment does not increase spontaneous cancer risk in mice, and may actually decrease it.
